Chronic inflammatory demyelinating polyradiculoneuropathy

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
5 Unique sponsors
6 Unique IMPs
5 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 2
— ATC code not specified 2
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Immunoglobulin 1 substance
FcRn antagonist 1 substance
Phase III: 2 Phase II: 3

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

2 trials
  • Dianthus Therapeutics Inc. Commercial
    DNTH103
    2024-517529-26-00 12 countries 2025 n=168
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    HUMAN NORMAL IMMUNOGLOBULIN; HUMAN NORMAL IMMUNOGLOBULIN, HYALURONIDASE (HUMAN RECOMBINANT)
    2024-517450-95-00 8 countries 2025 n=46
    Recruiting

Phase II

3 trials
  • Janssen - Cilag International Commercial
    HUMAN NORMAL IMMUNOGLOBULIN; NIPOCALIMAB
    2023-508425-28-00 8 countries 2022 n=65
    Recruiting
  • Nuvig Therapeutics Inc. Commercial
    NVG-2089
    2024-515386-34-00 6 countries 2025 n=99
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    RILIPRUBART
    2024-512345-16-00 6 countries 2021 n=56 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 1 Phase II 1
Nuvig Therapeutics Inc. Commercial 1 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 0
Dianthus Therapeutics Inc. Commercial 1 Phase III 1
Takeda Development Center Americas Inc. Commercial 1 Phase III 1
New trials by year
2021
1
2022
1
2025
3
← All indication landscapes